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Immune responses to sporozoite antigens and
their relationship to naturally acquired immunity
to malaria
B.M. Greenwood'
This paper reviews some of the epidemiological approaches that have been explored and gives some
examples of how these methods have been used to investigate naturally acquired immunity to sporozoite
infections.
Introduction
It is clear that man can naturally develop immunity to
malaria because in areas of high challenge most adults
remain free from severe clinical attacks and experi-
ence only occasional, low-level infections. Protective
immunity to malaria is achieved in a progressive
manner. Firstly, protection is acquired against death
or severe clinical disease, then against milder clinical
attacks, and finally against infection itself, although
the latter kind ofimmunity is usually only partial. The
immune mechanisms that are responsible for bringing
about these different degrees of protection remain
uncertain although the classical transfer experiments
done in the Gambia (3) showed that a component or
components of y-globulin preparations, probably
antibodies, play an important role. More information
as to which antibodies are involved could be obtained
by further passive transfer experiments using affinity
purified antibodies or, better still, human monoclonal
antibodies, but such studies raise difficult ethical
problems. So far, most attempts to define the compon-
ents of the immune response that are responsible for
naturally acquired protective immunity have involved
indirect epidemiological studies.
Methods and results
Epidemlological approaches to the Investigation
of te protective role of Individual Immune
responss In malaria
The following three types of study of increasing com-
plexity can be used to investigate the possible role of
a specific immune response to a malaria antigen in
protection against the infection.
1 Medical Research Council Laboratories, Fajara, Banjul, Gambia.
1. Study of adult immune subjects and non-immune
controls
The first approach to the characterization of an im-
mune response considered to be a possible mediator
of protective immunity is to show that the response
can be found in the majority of healthy adults living in
an area of high malaria transmission but not in non-
exposed controls. Investigation of the latter group is
important, especially for peptide antigens, because
cell-mediated immune responses to malaria peptides
have been found in some subjects who have never
been exposed to the infection, perhaps reflecting ex-
posure to a cross-reacting antigen. If the response
under investigation cannot be demonstrated in im-
mune adults it is unlikely to play a part in naturally
acquired protective immunity although the reverse is
not necessarily the case.
2. Cross-sectional surveys of an exposed population
A cross-sectional survey of a randomly selected
sample of a population exposed to malaria is relat-
ively easy to do and it can give some useful informa-
tion about the possible protective role ofan individual
immune response. Cross-sectional surveys are of most
value when immunological measurements are com-
bined with conventional malariometric recordings
such as the spleen and parasite rate. Detection of a
positive correlation between the immunological test
under investigation and the presence of parasitaemia
or splenomegaly suggests that it simply reflects expos-
ure whilst a negative correlation is compatible with a
protective role.
In populations where malaria is endemic the
incidence rate of attacks of clinical malaria and the
prevalence of malaria parasitaemia and of splenomeg-
aly are strongly age-determined. Comparison of the
age-dependent profile of the immune response being
investigated with variations in the prevalence of mal-
aria by age may provide useful information on the
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likely role of this response in protective immunity. If
the age-dependent pattern of an immune response
parallels that of parasitaemia, declining with increas-
ing age, it is probable that it reflects only exposure to
the infection. A response which rises in parallel with a
decline in parasitaemia and which is sustained is more
likely to have a protective role.
3. Longitudinal cohort studies
Longitudinal cohort studies are probably the most
satisfactory epidemiological approach used so far to
investigate the possible protective role of individual
immune responses to malaria antigens but they are
subject to many potentially confounding variables.
The basic design of such studies is simple (Fig. 1);
measurements of the immune response under invest-
igation are made in a group of volunteers exposed to
malaria and the results obtained related to the sub-
sequent malaria experience of the study subjects. In
their simplest form, studies of this kind assume that all
the individuals entering the trial have the same genetic
susceptibility to malaria and a similar exposure to
infection throughout the period of observation.
Neither of these conditions is ever likely to be met
under natural conditions. It may be possible to reduce
variations in genetic susceptibility among the study
subjects by excluding those with genetically deter-
mined characteristics that influence the susceptibility
to malaria, e.g., a haemoglobinopathy or a-thalas-
saemia, or by making allowance for specific genetic
factors in the final analysis. This is difficult to do and
studies undertaken so far have relied on randomiz-
ation to distribute equal numbers of subjects with
genetically determined resistance to infection to
groups with and without the immune response under
investigation. It may be possible to take some account
of variations in exposure by measuring this directly
and accounting for it in the final analysis. We are
currently experimenting with this approach in the
Gambia by recording the numbers of mosquitos in-
side the bed nets of study individuals.
If the immune response under investigation is
directed at a variable part of a malaria antigen, strain
variation will pose a further potentially confounding
Fig. 1: Design for a longitudinal cohort sudy to Invesigat the Influence of an Immune response on protecve Immunity
to malaria.
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factor because assays done with material derived from
a parasite which differs considerably in its antigenic
profile from the parasite circulating in the study com-
munity at the time of the investigation may not give
meaningful results.
Despite the many potential pitfalls to a longitud-
inal cohort study we found that a study of this kind
undertaken in a small group of Gambian children was
able to demonstrate convincingly an association
between the use of bed nets and the possession of
haemoglobin genotype AS with protection against
malaria (12).
The Immune response to sporozolte antigens
and naturally acquired protctve Immunity
to malaria
In this section, the results of studies carried out in
the Gambia using the epidemiological approaches
described above are summarized.
1. Immune responses to sporozoite antigens in
immunes and non-immunes
Early attempts to demonstrate antibodies to sporo-
zoites in adult malaria-immune Gambians were un-
successful (1), but in 1979 Nardin et al., reported that
antibodies to the circumsporozoite protein (CSP)
could be demonstrated in the sera of many Gambian
adults both by the circumsporozoite precipitation
reaction and, more frequently, by immunofluor-
escence (Fig. 2). Antibodies were found much less
frequently in children than in adults, except during the
Fig. 2: The prevalence of sporozolte antibodles In a rural
area of the Gambia (sera were diluted 1:4).
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first 6 months of life when maternally transmitted
antibodies could be found (14). Similar results have
been obtained subsequently using radioimmuno-
assays or ELISAs to the CSP repeat peptides
(NANP)3 or (NANP)40 (12, 17). However, antibodies
to CSP repeat peptides cannot be detected in sera
from a small proportion of apparently immune adults
suggesting that the immune response to this antigen
might be genetically restricted and that it is not
essential for protection. Antibodies to NANP repeats
are not found in non-exposed adults. In a study of a
small group of expatriates resident in the Gambia
anti-CSP antibodies were found, with only one ex-
ception, only in those who had been resident in the
Gambia or another malaria endemic area for 5 years
or more (K. Marsh et al., unpublished).
Recently studies of immune responses to CSP in
adult immune Gambians and in non-immunes have
been extended to assays of cell-mediated immunity
(CMI). Good et al. (9) measured lymphocyte pro-
liferative responses to 29 overlapping CSP peptides
spanning the entire length of the CSP molecule in 35
healthy adult Gambians; 21 responded to at least one
peptide. Analysis of the response of the whole group
to each peptide showed three immunodominant sites,
each located within the variable region of the mole-
cule (Fig. 3). No significant proliferation was observed
with lymphocytes obtained from six non-immune
controls. To investigate further the importance of
strain variation De Groot et al. (4) measured in the
same adult donors the lymphocyte proliferative re-
sponse to six peptides. Three peptides corresponded
to the 326-345 region of the CSP molecule (TH2R) of
three different strains of Plasmodiumfalciparum (7G8,
Wellcome and LE5) and three to the 361-380 region
(TH3R) of the same strains. Considerable variability
in responsiveness was observed, some subjects respond-
ing to the peptide of only one strain whilst others
responded to all three (Table 1). Two of nine non-
exposed control subjects showed a modest prolifer-
ative response to one or other peptide.
In a further series of studies we are investigating
the possible protective role of CD8 cells against
sporozoites by studying the ability of lymphocytes
obtained from adult immune Gambians to kill B cells
expressing CSP peptides as a result of infection with a
recombinant vaccinia virus. So far, specific killing
has not been demonstrated but experiments are
continuing.
2. Cross-sectional surveys of immune responses
to sporozoite antigens
50+* The prevalence of antibodies to (NANP)3, as deter-
mined by radioimmunoassay, was studied in a rural
Gambian community by Marsh et al. (12) (Fig. 4). The
prevalence of anti-(NANP)3 antibodies began to rise
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Fig. 3: Lymphocyte prolifrative responses of 35 adult Immune Gamblans to 29 overlapping poptidos panning the entire
length of the CS protein.
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Table 1: Lymphocyte proliferative responses of 40 adult
Immune Gamblans to two CSP peptides corresponding to
the sequence found In three straIns of Plasmodlum halc-
parum
Peptide
No. of subjects
responding TH 2 R (326-345) TH 3 R (361-380)
Three strains 13 10
Two strains 8 10
One strain 9 4
None 10 12
Not tested - 4
Total 40 40
a Data from ref. 4.
only at about the age of 10 years. Comparison of the
prevalence curve for antibodies to (NANP)3 with the
age-dependent pattern of other features of malaria
showed that the incidence of clinical attacks of mal-
aria declined well before the appearance of antibodies
to (NANP)3 but that the appearance of those antibod-
ies corresponded more closely with a decline in the
prevalence of parasitaemia. These findings suggest
that antibodies to (NANP)3 could play a part in
protection against infection but not in protection
against disease severity.
In 1988, CMI responses to the CSP peptides
THIR and TH2R were measured in approximately
500 Gambian subjects aged 1-70 years during a cross-
Fig. 4: The relationship between sporozoite antibodies
and protection against clinical malaria and against mal-
aria Infection In a rural area of the Gambla.8
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'Protection against clinical malaria is expressed as the reciprocal
of the number of clinical attacks per child per year determined by
weekly morbidity surveillance. Protection against infection is indi-
cated by the percentage of subjects with a negative blood film at
the end of the rainy season.
sectional survey undertaken just before the malaria
transmission season. Results from this study are now
in press (Riley, E.M. et al. Trans. Roy. Soc. Trop. Med.
Hyg.).
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3. Longitudinal cohort studies
Two longitudinal studies of the possible role of anti-
bodies to CSP peptides in protection against malaria
have been done in the Gambia. In the first study,
antibodies to (NANP)3 were measured by radioim-
munoassay in 124 Wollof children aged 1-11 years
and related to the malaria experience of these children
during the following rainy season (12). Clinical attacks
of malaria were recorded a little less frequently in
children who had anti4NANP)3 antibodies than in
children who had not (Table 2) and, at the end of the
rainy season, the prevalence of parasitaemia was sig-
nificantly lower in children who were seropositive at
the beginning of the rainy season than in those who
were seronegative. This difference was not observed in
adults.
A second study was undertaken in a group of
Fula children aged 1-9 years resident in a different
group of villages who were participating in a trial of
bed nets (17). In this study, in which antibodies were
measured by an ELISA to (NANP)40 (6), the overall
prevalence of antibodies in children was higher than
that recorded in the first study. Children who were
seropositive at the beginning of the rainy season were
again found to experience fewer clinical attacks of
malaria during the following months than children
who were not (Table 3) but, at the end of the rainy
season, the overall prevalence of parasitaemia was
similar in the two groups.
In 1988, a third longitudinal cohort study was
done in which the relationship between CMI re-
sponses to CSP peptides and protection against mal-
aria was investigated. At the beginning of the rainy
season lymphocyte proliferative and y-interferon re-
sponses to the CSP peptides THIR and TH2R of 3
strains were measured in 380 children aged 3-8 years.
Between 10% and 30% of children responded to
individual peptides. During the subsequent few
months about half the children developed a clinical
attack of malaria and others developed an asympto-
matic parasitaemia. The results of the clinical and
laboratory data sets are now being analysed.
Discussion
Comparison of the results of Gamblan studies
of sporozolte Immunity with those of studies
done elsewhere
The prevalence of anti-sporozoite antibodies has been
measured in a number of communities in different
Table 2: Antibodies to (NANP)3 measured by radlolmmunoasay In rural Gamblans at the beginning of the rainy season
and their relationship to subsquent malaria infetiona
Age 1-11 years Age 12 years or more
Positive (n= 15) Negative (n=109) Positive (n=46) Negative (n= 18)
Clinical attacks of malaria (mean per child) 0.43 0.67 NDb ND
Parasitaemia at end of rainy season (%) 59 29c 280
P= 0.01
a Data from ref. 12.
b ND: not detected.
c Age-standardized.
Table 3: Antibodies to (NANP)4W measured by ELISA in Gamblan children aged 14 years and their relationship to
subsequent malaria infction'
Antibody status
Seropositive Seronegative
Clinical attacks of malaria (mean per child) 0.17 0.22
(21/124) (42/193)
Clinical attacks of malaria with high parasitaemia (mean per child) 0.07 0.17
(9/124) (33/193)
Parasitaemia at the end of rainy season (%) 66.1 50.0
(74/112) (90/180)
Parasitaemia >5000 per pl at the end of the rainy season (%) 17.0 19.4
(19/112) (35/180)
a Data from Snow et al., unpublished.
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Table 4: Summary of cohort studies Investigating the relationship between sporozolte Immunity and protection against
Infecton
Country and
reference Age group Measurement Findings
Burkina Faso (8) Adults Antibody to (NANP)3 Decreased incidence of infection in low transmission
periods; no protection in high transmission periods
Gambia (12) 1-11 years Antibody to (NANP)3 Fewer clinical attacks (borderline) and reduced in-
cidence of infection
Gambia (17) 1-9 years Antibody to (NANP)40 Fewer clinical attacks (high parasitaemia), no reduc-
tion in incidence of infection
Kenya (11) Adults Several antibody assays No protection against infection
Kenyaa Adults CMI responses Reduced incidence of infection in responders
to CSP peptides
Thailandb All ages Antibody to R32tet32 No protection against infection
Thailand (16) 5-15 years Antibody to R32tet32 No protection against infection
' See footnote b below for reference.
b See footnote a below for reference.
malaria endemic areas. These studies have shown that
the age at which antibodies first appear is closely
related to the level of exposure. Thus, Druihle et al. (7)
showed that in an area of Burkina Faso where adults
are exposed to at least 100 infective bites per year
most children aged 2-5 years had modest titres of
fluorescent antibodies to sporozoites. In contrast, in
an area of northern Senegal where exposure is only
about one infective bite per year the antibodies were
found only in older children and adults. Similarly,
Esposito et al. (8) detected in Burkina Faso a direct
relationship between the prevalence and titre of anti-
bodies to (NANP)3 in children and the entomological
inoculation rate recorded in the community in which
the children lived. In areas of high transmission in
Kenya (2) and in the United Republic of Tanzania (5)
antibodies were found in a high proportion of young
children. In contrast, in communities in Indonesia (10)
and in Thailand (18)8 with a lower level of transmis-
sion a similar pattern to that observed in the Gambia
was recorded, only a few children under the age of 10
years having high titres of antibody to sporozoites or
CSP peptides. Surprisingly, a recent study in U.S.
Peace Corps volunteers working in Africa showed
that up to one half developed antibodies to (PNAN),
after only two years of exposure (13). Perhaps adults
can more readily mount an antibody response to CSP
peptides than children.
Several studies have investigated the relationship
between antibodies to sporozoites and protection
against malaria (Table 4) and some consensus is be-
ginning to emerge. It is clear that antibodies to CSP
peptides at the titres produced as a result of natural
infection have, at the most, a very modest protective
effect against malaria infection. Clear negative results
have been obtained with cohort studies done in
Kenya (11) and in Thailand (16).a The latter study,
performed in Karen children, used a case-control
technique. The results of the investigation in Kenya
are particularly convincing, because in this investiga-
tion the sporozoite antibodies were measured by sev-
eral different methods; none showed any suggestion of
a protective effect. In Burkina Faso, cross-sectional
surveys showed no protection against infection during
the main malaria transmission season but some pro-
tection was seen in adults at the beginning and at the
end of the rainy season when the pressure of infection
was less (8) Our findings in the Gambia of some
protection for seropositive subjects is in keeping with
these observations because in this country, the pres-
sure of infection, even at the height of the malaria
transmission season, is less than that which prevails in
the areas of Kenya and Burkina Faso where compar-
able studies have been done.
The results of only one longitudinal cohort study
relating the CMI response to sporozoite antigens to
protection against infection have been reported so
far.b This study, which was carried out in an area of
high transmission in Kenya, showed that of 25 adult
volunteers who were infected with malaria during the
'Hon, S.L. et al. Identification ofa potentially protective T-cell
epitope on the Plasmodium falciparum CS protein. Paper pre-
sented at a meeting on the immunological aspects of malaria
epidemiology, World Health Organization, Geneva, September
1988.
b Webintr, H.K. et al. Epidemiology of anti-sporozoite immunity in
Thailand. Paper presented at a meeting on the immunological
aspects of malaria epidemiology, World Health Organization,
Geneva, September 1988.
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observation period only two responded to peptide
361-380 and only one to peptide 371-390 at the onset
of the trial. In contrast, all three subjects who did not
become infected responded to peptide 361-380 and
two responded to peptide 371-390. These preliminary
results are exciting but they need confirmation in
trials involving larger numbers of subjects, such as the
one which was done in the Gambia in 1988 in which
380 children were studied.
Conclusion
It is unlikely that epidemiological studies of the kind
that have been described in this paper will ever be able
to demonstrate convincingly that any specific immune
response plays a critical role in protective immunity
to malaria because such studies are inevitably subject
to many potentially confounding factors. Further-
more, when an immune response is shown to be
related to clinical protection this does not establish
cause and effect since the immune response being
studied may be linked to another more important
immune mechanism which was not investigated.
Epidemiological studies are likely to be better at
demonstrating a negative rather than a positive effect
and they have already provided good evidence that a
CSP vaccine, which could only induce antibody levels
comparable to those seen as a result of natural infec-
tion, would be very unlikely to provide any useful
protective immunity in areas of high malaria trans-
mission. Epidemiological studies may provide some
helpful guidelines to molecular biologists and
immunologists engaged in vaccine development on
the directions that their work should take.
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